$TNXP EXPECT BIGGER MOVES NEXT WEEK.
IT HAS ALREADY BEEN A EVENTFUL WEEK FOR
TNXP
WITH CAPITAL RAISE ISSUES AND A NEW PIPELINE DRUG CANDIDATE UPDATE. NEST WEEK COULD BE EQUALLY IMPORTANT AS ON TUESDAY THE COMPANY RELEASES DATA ON TNX-102 PHARMACOKINTEC . THE STOCK IS SETTING UP NICELY FOR THE WEEK TO COME.
COMPANY PROFILE
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which engages in discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. It focuses on delivering a safe and effective long-term treatment for posttraumatic stress disorder. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya.
TNXP
WITH CAPITAL RAISE ISSUES AND A NEW PIPELINE DRUG CANDIDATE UPDATE. NEST WEEK COULD BE EQUALLY IMPORTANT AS ON TUESDAY THE COMPANY RELEASES DATA ON TNX-102 PHARMACOKINTEC . THE STOCK IS SETTING UP NICELY FOR THE WEEK TO COME. COMPANY PROFILE
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which engages in discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. It focuses on delivering a safe and effective long-term treatment for posttraumatic stress disorder. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media